SCHEMBL458428

SCHEMBL458428

CCCCCNC1=CC(=O)C(=O)c2cccnc21

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S100A4 P26447 5/20 0.68
ALDH1A1 P00352 2/20 0.63
APAF1 O14727 1/20 0.63
TDP2 O95551 4/20 0.49
NSD2 O96028 3/20 0.49
PAX8 Q06710 2/20 0.49
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
GUCY1B2 O75343 1/20 0.46
MAPT P10636 1/20 0.46
GUCY1A2 P33402 1/20 0.46
GUCY1A1 Q02108 1/20 0.46
GUCY1B1 Q02153 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
MALT1 Q9UDY8 3/20 0.46
G6PD P11413 1/20 0.45
ABL1 P00519 1/20 0.44
PLCG1 P19174 1/20 0.44
CES1 P23141 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15698467 0.88 S100A4 (0.63) S100A4ALDH1A1APAF1TDP2NSD2
SCHEMBL3317054 0.83 APAF1 (0.91) S100A4ALDH1A1APAF1NSD2MEN1
SCHEMBL2599332 0.81 S100A4 (0.71) S100A4ALDH1A1APAF1TDP2NSD2
SCHEMBL2599211 0.81 S100A4 (1.00) S100A4ALDH1A1APAF1TDP2NSD2
SCHEMBL3315349 0.79 ALDH1A1 (0.72) S100A4ALDH1A1APAF1MAPTSMN1; SMN2
SCHEMBL30587688 0.79 ALDH1A1 (0.72) S100A4ALDH1A1APAF1MAPTSMN1; SMN2
SCHEMBL21814471 0.77 ALDH1A1 (0.70) S100A4ALDH1A1APAF1MAPTSMN1; SMN2
SCHEMBL21814443 0.77 ALDH1A1 (0.70) S100A4ALDH1A1APAF1MAPTSMN1; SMN2
SCHEMBL21814535 0.77 ALDH1A1 (0.70) S100A4ALDH1A1APAF1MAPTSMN1; SMN2
SCHEMBL21814430 0.77 ALDH1A1 (0.70) S100A4ALDH1A1APAF1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022070-A1 Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use EMORY UNIVERSITY (US) 2012-01-26 US claimed
WO-2010042500-A2 HEAT SHOCK PROTEIN 90 INHIBITORS, METHODS OF PREPARING SAME, AND METHODS FOR THEIR USE EMORY UNIVERSITY (US) 2010-04-15 WO claimed
US-20120022070-A1 Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use EMORY UNIVERSITY (US) 2012-01-26 US disclosed
WO-2010042500-A2 HEAT SHOCK PROTEIN 90 INHIBITORS, METHODS OF PREPARING SAME, AND METHODS FOR THEIR USE EMORY UNIVERSITY (US) 2010-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022070-A1 Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use HSP90AB1, HSP90AA1, HSP90AB2P S100A4 1434/4885ALDH1A1 2606/4885APAF1 1220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.